Table 1 Demographic and clinical characteristics of the study population with AF at baseline according to ischemic stroke event
Variables | Without Stroke (n = 222) | With Stroke (n = 46) | P value |
|---|---|---|---|
Age (y) | 73.4 ± 10.5 | 73.2 ± 8.8 | 0.89 |
Gender male n (%) | 86 (39) | 19 (41) | 0.74 |
DM n (%) | 150 (68) | 35 (76) | 0.30 |
Dialysis vintage (years) | 0.0 (0.0–3.0) | 0.0 (0.0–2.0) | 0.66 |
Kt/V | 1.34 ± 0.18 | 1.41 ± 0.18 | 0.02 |
Vascular access | 0.70 | ||
Arterio-venous fistula n (%) | 78 (35) | 21 (46) | |
Arterio-venous graft n (%) | 16 (7) | 4 (9) | |
Central venous Catheter n (%) | 128 (58) | 21 (46) | |
Heparin dose during HD session (units) | 2500 (1250–2500) | 2500 (0–2500) | 0.28 |
Comorbidity index | 8.7 ± 3.3 | 9.1 ± 2.9 | 0.44 |
Functional status (need in nursing care) n (%) | 120 (55) | 28 (61) | 0.41 |
Dementia n (%) | 36 (16) | 10 (22) | 0.39 |
A-V access thrombosis n (%) | 42 (19) | 15 (33) | 0.06 |
Left atrium size (cm) | 4.3 ± 0.7 | 4.4 ± 0.5 | 0.94 |
Time since AF diagnosis (years) | 3.0 (1.0–7.0) | 4.0 (1.0–7.8) | 0.45 |
All-cause death n (%) | 175 (79) | 41 (89) | 0.15 |
Warfarin use n (%) | 76 (34) | 15 (33) | 0.87 |
Aspirin use n (%) | 126 (57) | 27 (59) | 0.86 |
Clopidogrel use n (%) | 45 (20) | 15 (33) | 0.29 |
Dual antiplatelet therapy n (%) | 33 (15) | 7 (15) | 0.96 |
Enoxaparin use n (%) | 29 (13) | 6 (13) | 0.97 |
INR | 1.2 (1.1–1.5) | 1.2 (1.1–1.5) | 0.95 |
Hb (g/dL) | 10.0 ± 1.8 | 10.6 ± 1.5 | 0.12 |
Platelets(× 103/mm3) | 191.1 ± 70.3 | 216.4 ± 80.1 | 0.27 |
Mean CHA2DS2-VASc score | 4.9 ± 1.6 | 5.7 ± 1.6 | 0.005 |
CHA2DS2-VASc score | 0.06 | ||
0 n (%) | 1 (0.5) | 0 (0) | |
1 n (%) | 5 (2.3) | 0 (0) | |
2 n (%) | 11 (4.9) | 1 (2.2) | |
3 n (%) | 20 (9.0) | 4 (8.7) | |
4 n (%) | 44 (19.8) | 6 (13.0) | |
5 n (%) | 64 (28.8) | 7 (15.2) | |
6 n (%) | 40 (18.0) | 16 (34.8) | |
7 n (%) | 25 (11.3) | 5 (10.9) | |
8 n (%) | 10 (4.5) | 5 (10.9) | |
9 n (%) | 2 (0.9) | 2 (4.3) |